Search results
California could end ban on funding homeless sober living. Are Democrats moving right on drugs?
Sacramento Bee via AOL· 4 hours ago“But also, Prop. 1 will fund other types of treatment ... and long-term recovery drug housing is an...
New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone)...
Benzinga· 6 days agoSwitching to UZEDY at four weeks after the last dose of once-monthly paliperidone palmitate provided the most comparable pharmacokinetic (PK) profile based on the relevant PK modeling data Additional data include
Valley County OD deaths underscore rural challenges in drug treatment, services
KTVB Boise· 4 days agoThis article originally appeared in the Idaho Press. As the nation’s opioid crisis continues, even...
SARCOMA CLINICAL TRIAL FUNDED BY STAND UP TO CANCER REDUCES RISK OF RELAPSE BY 43%
Tehachapi News· 4 days agoFor the last three decades, breakthroughs have been sparse for soft tissue sarcomas, which are rare cancers that affect muscles, fat and other connective tissues. Today, a global team of researchers ...
FDA Roundup: May 31, 2024
The Pilot News· 7 days agoToday, the FDA approved mRESVIA (Respiratory Syncytial Virus Vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV ...
MD Anderson Research Highlights for June 5, 2024 | Newswise
Newswise· 2 days agoThe University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These
Live from ASCO 2024 | Ascentage Pharma Releases Updated Data of FAK/ALK/ROS1 Inhibitor APG-2449 in...
Benzinga· 5 days agoSUZHOU, China, and ROCKVILLE, Md., June 1, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related
'Outstanding' 5 Year PFS With Lorlatinib in ALK+ NSCLC
Medscape· 6 days agoFive-year follow-up data from the landmark CROWN trial shows significant progression-free survival in ALK+ NCSLC, but some experts question the use of crizotinib as the comparator drug.